COMMUNIQUÉS West-GlobeNewswire

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
31/03/2026
PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progression A Phase 2 proof-of-concept study of SCY-770 [...]
60 Degrees Pharmaceuticals Announces 2025 Annual Results
31/03/2026
FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc [...]
Weight Watchers Announces Best in Market Self-Pay Wegovy® Pricing for Med+ Members and the Launch of Preferred Subscription Pricing for Wegovy via NovoCare®
31/03/2026
Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers’ integrated [...]
Shock Top Launches High Voltage, Its First-Ever High-ABV Beer
31/03/2026
A Double Wheat Brew that Surges with Big, Shocking Citrus, Shock Top High Voltage is Boldly Strong at 9.6% ABV PORTLAND, Ore., March 31, 2026 (GLOBE NEWSWIRE) -- Shock Top , a craft beer icon and brand by Tilray [...]
Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service
31/03/2026
Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service Irving, Texas, USA – March 31, 2026 – Atos , a global leader of AI-powered digital transformation today announced a significant advancement [...]
Transactions in connection with share buy-back program
31/03/2026
Company announcement no. 8 - 26 31 March 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre|CISION® exatecan peptide drug conjugate
31/03/2026
Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from the trial expected later this year LONDON and PHILADELPHIA, March 31, 2026 (GLOBE NEWSWIRE) -- [...]
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
31/03/2026
PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative long-term visual [...]
CancerVax Reports Successful Initial Mouse Study with Breakthrough Results
31/03/2026
First biodistribution study of the Company’s novel targeted lipid nanoparticle achieved systemic circulation with the potential to target many types of cancer Lehi, UT, March 31, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, [...]
SAFE - Forte dynamique de développement au Venezuela
31/03/2026
Forte dynamique de développement au Venezuela Fleurieux-sur-l’Arbresle - France - le 31 mars 2026 à 8h. Après la signature d'un accord de distribution et le succès de la première chirurgie annoncés le 24 avril 2025 , [...]
EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis
31/03/2026
Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European Commission (EC) [...]
Standing Ovation lève $34,2 M pour la commercialisation à grande échelle de sa technologie de rupture visant à produire des protéines laitières par fermentation, une réponse souveraine et durable à l’explosion de la demande en protéines
31/03/2026
COMMUNIQUÉ DE PRESSE Standing Ovation lève $34,2 millions pour la commercialisation à grande échelle de sa technologie de rupture visant à produire des protéines laitières par fermentation de précision, une réponse [...]
Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein
31/03/2026
PRESS RELEASE Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in [...]
BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health
31/03/2026
BASEL, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM) diseases. BioVersys joins [...]
Communiqué de presse : Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte
31/03/2026
Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Rezurock est maintenant approuvé dans l’UE pour les adultes et les enfants âgés de 12 ans et plus atteints de [...]
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
31/03/2026
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional [...]
Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
31/03/2026
Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients [...]
ONWARD Medical Reports Full Year 2025 Financial and Operating Results, Highlighting Strong US Commercial Performance and Major Pipeline Milestones
31/03/2026
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, March 31, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. ( [...]
Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11
31/03/2026
PITTSBURGH, March 30, 2026 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today that it filed a voluntary petition for relief under [...]

Pages